Testing axelopran for advanced cancer patients on opioids
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin clinical trials.
This trial tests if axelopran can help people with advanced prostate, breast, pancreatic, or lung cancer who are taking opioid pain medicines. It aims to see if the drug is safe and helps with bowel function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced prostate, breast, pancreatic, or non-small cell lung cancer that has spread or come back after standard treatment.
- You are taking an opioid pain medicine averaging at least 5 mg of morphine equivalent per day over the last 3 days.
- You have not had cancer treatment in the last 2 weeks and are willing to pause next treatment for about 6 weeks to see the effect on your cancer.
- You have not had major bowel surgery, active bowel problems, or untreated brain metastases.
- You can take oral medicines and are not pregnant or breastfeeding, and you agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new immunotherapy drug called JANX014 in men with advanced prostate cancer that has stopped responding to hormone treatments. The trial aims to find the right dose and see if this drug can help slow or stop cancer growth.
This study tests a new drug called AGX101 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can shrink tumors or slow their growth.
This Phase 1/2 trial tests AMXI-5001 in people with advanced cancers that have progressed or stopped responding to standard treatments. It’s mainly designed to find the safest dose and see early signs the treatment might work.
This trial tests an investigational drug called QXL138AM for people with advanced solid tumors or multiple myeloma that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
This Phase 1 trial tests JANX007 in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite standard hormone treatment). It aims to find a safe dose and see whether the treatment can shrink tumors or slow progression.
This trial tests a new drug called axelopran in patients with advanced skin cancer (melanoma) whose tumors stopped responding to a common immunotherapy called anti-PD-1 drugs. The goal is to see if axelopran can help when standard immunotherapy no longer works.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.